Literature DB >> 24806994

CCR2 deficiency impairs macrophage infiltration and improves cognitive function after traumatic brain injury.

Christine L Hsieh1, Erene C Niemi, Sarah H Wang, Chih Cheng Lee, Deborah Bingham, Jiasheng Zhang, Myrna L Cozen, Israel Charo, Eric J Huang, Jialing Liu, Mary C Nakamura.   

Abstract

Traumatic brain injury (TBI) provokes inflammatory responses, including a dramatic rise in brain macrophages in the area of injury. The pathway(s) responsible for macrophage infiltration of the traumatically injured brain and the effects of macrophages on functional outcomes are not well understood. C-C-chemokine receptor 2 (CCR2) is known for directing monocytes to inflamed tissues. To assess the role of macrophages and CCR2 in TBI, we determined outcomes in CCR2-deficient (Ccr2(-/-)) mice in a controlled cortical impact model. We quantified brain myeloid cell numbers post-TBI by flow cytometry and found that Ccr2(-/-) mice had greatly reduced macrophage numbers (∼80-90% reduction) early post-TBI, compared with wild-type mice. Motor, locomotor, and cognitive outcomes were assessed. Lack of Ccr2 improved locomotor activity with less hyperactivity in open field testing, but did not affect anxiety levels or motor coordination on the rotarod three weeks after TBI. Importantly, Ccr2(-/-) mice demonstrated greater spatial learning and memory, compared with wild-type mice eight weeks after TBI. Although there was no difference in the volume of tissue loss, Ccr2(-/-) mice had significantly increased neuronal density in the CA1-CA3 regions of the hippocampus after TBI, compared with wild-type mice. These data demonstrate that Ccr2 directs the majority of macrophage homing to the brain early after TBI and indicates that Ccr2 may facilitate harmful responses. Lack of Ccr2 improves functional recovery and neuronal survival. These results suggest that therapeutic blockade of CCR2-dependent responses may improve outcomes following TBI.

Entities:  

Keywords:  CCR2; brain injury; chemotaxis; inflammation; macrophage

Mesh:

Substances:

Year:  2014        PMID: 24806994      PMCID: PMC4545982          DOI: 10.1089/neu.2013.3252

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  80 in total

1.  The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood.

Authors:  Makiko Mizutani; Paula A Pino; Noah Saederup; Israel F Charo; Richard M Ransohoff; Astrid E Cardona
Journal:  J Immunol       Date:  2011-11-11       Impact factor: 5.422

2.  A mouse model of human repetitive mild traumatic brain injury.

Authors:  Michael J Kane; Mariana Angoa-Pérez; Denise I Briggs; David C Viano; Christian W Kreipke; Donald M Kuhn
Journal:  J Neurosci Methods       Date:  2011-09-12       Impact factor: 2.390

3.  CCR2 recruits an inflammatory macrophage subpopulation critical for angiogenesis in tissue repair.

Authors:  Sebastian Willenborg; Tina Lucas; Geert van Loo; Johanna A Knipper; Thomas Krieg; Ingo Haase; Bent Brachvogel; Matthias Hammerschmidt; Andras Nagy; Napoleone Ferrara; Manolis Pasparakis; Sabine A Eming
Journal:  Blood       Date:  2012-05-10       Impact factor: 22.113

Review 4.  Chronic neuropathologies of single and repetitive TBI: substrates of dementia?

Authors:  Douglas H Smith; Victoria E Johnson; William Stewart
Journal:  Nat Rev Neurol       Date:  2013-03-05       Impact factor: 42.937

Review 5.  Monocyte recruitment during infection and inflammation.

Authors:  Chao Shi; Eric G Pamer
Journal:  Nat Rev Immunol       Date:  2011-10-10       Impact factor: 53.106

6.  Inhibitory control after traumatic brain injury in children.

Authors:  Katia J Sinopoli; Maureen Dennis
Journal:  Int J Dev Neurosci       Date:  2011-11-11       Impact factor: 2.457

Review 7.  Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases.

Authors:  Shambhunath Bose; Jungsook Cho
Journal:  Arch Pharm Res       Date:  2013-06-15       Impact factor: 4.946

8.  Traumatic brain injury induces macrophage subsets in the brain.

Authors:  Christine L Hsieh; Charles C Kim; Bryan E Ryba; Erene C Niemi; Jennifer K Bando; Richard M Locksley; Jialing Liu; Mary C Nakamura; William E Seaman
Journal:  Eur J Immunol       Date:  2013-06-05       Impact factor: 5.532

9.  Therapeutic siRNA silencing in inflammatory monocytes in mice.

Authors:  Florian Leuschner; Partha Dutta; Rostic Gorbatov; Tatiana I Novobrantseva; Jessica S Donahoe; Gabriel Courties; Kang Mi Lee; James I Kim; James F Markmann; Brett Marinelli; Peter Panizzi; Won Woo Lee; Yoshiko Iwamoto; Stuart Milstein; Hila Epstein-Barash; William Cantley; Jamie Wong; Virna Cortez-Retamozo; Andita Newton; Kevin Love; Peter Libby; Mikael J Pittet; Filip K Swirski; Victor Koteliansky; Robert Langer; Ralph Weissleder; Daniel G Anderson; Matthias Nahrendorf
Journal:  Nat Biotechnol       Date:  2011-10-09       Impact factor: 54.908

10.  Temporal changes in cell marker expression and cellular infiltration in a controlled cortical impact model in adult male C57BL/6 mice.

Authors:  Xuemei Jin; Hiroshi Ishii; Zhongbin Bai; Takahide Itokazu; Toshihide Yamashita
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

View more
  75 in total

Review 1.  Neuroimmune interaction in seizures and epilepsy: focusing on monocyte infiltration.

Authors:  Dale B Bosco; Dai-Shi Tian; Long-Jun Wu
Journal:  FEBS J       Date:  2020-06-15       Impact factor: 5.542

Review 2.  Inflammatory reaction after traumatic brain injury: therapeutic potential of targeting cell-cell communication by chemokines.

Authors:  Stefka Gyoneva; Richard M Ransohoff
Journal:  Trends Pharmacol Sci       Date:  2015-05-13       Impact factor: 14.819

Review 3.  Targeting innate immunity for neurodegenerative disorders of the central nervous system.

Authors:  Katrin I Andreasson; Adam D Bachstetter; Marco Colonna; Florent Ginhoux; Clive Holmes; Bruce Lamb; Gary Landreth; Daniel C Lee; Donovan Low; Marina A Lynch; Alon Monsonego; M Kerry O'Banion; Milos Pekny; Till Puschmann; Niva Russek-Blum; Leslie A Sandusky; Maj-Linda B Selenica; Kazuyuki Takata; Jessica Teeling; Terrence Town; Linda J Van Eldik
Journal:  J Neurochem       Date:  2016-09       Impact factor: 5.372

4.  Microglial/Macrophage Polarization Dynamics following Traumatic Brain Injury.

Authors:  Alok Kumar; Dulce-Mariely Alvarez-Croda; Bogdan A Stoica; Alan I Faden; David J Loane
Journal:  J Neurotrauma       Date:  2015-12-29       Impact factor: 5.269

5.  Targeting Kv1.3 channels to reduce white matter pathology after traumatic brain injury.

Authors:  Thomas M Reeves; Patricia A Trimmer; Beverly S Colley; Linda L Phillips
Journal:  Exp Neurol       Date:  2016-06-11       Impact factor: 5.330

Review 6.  Neuroimmunology of Traumatic Brain Injury: Time for a Paradigm Shift.

Authors:  Yasir N Jassam; Saef Izzy; Michael Whalen; Dorian B McGavern; Joseph El Khoury
Journal:  Neuron       Date:  2017-09-13       Impact factor: 17.173

7.  NOX2 drives M1-like microglial/macrophage activation and neurodegeneration following experimental traumatic brain injury.

Authors:  Alok Kumar; James P Barrett; Dulce-Mariely Alvarez-Croda; Bogdan A Stoica; Alan I Faden; David J Loane
Journal:  Brain Behav Immun       Date:  2016-07-28       Impact factor: 7.217

8.  The role of the immune system during regeneration of the central nervous system.

Authors:  K Z Sabin; K Echeverri
Journal:  J Immunol Regen Med       Date:  2019-11-05

9.  Traumatic Brain Injury in hTau Model Mice: Enhanced Acute Macrophage Response and Altered Long-Term Recovery.

Authors:  Olga N Kokiko-Cochran; Maha Saber; Shweta Puntambekar; Shane M Bemiller; Atsuko Katsumoto; Yu-Shang Lee; Kiran Bhaskar; Richard M Ransohoff; Bruce T Lamb
Journal:  J Neurotrauma       Date:  2017-11-01       Impact factor: 5.269

10.  Infiltrating monocytes promote brain inflammation and exacerbate neuronal damage after status epilepticus.

Authors:  Nicholas H Varvel; Jonas J Neher; Andrea Bosch; Wenyi Wang; Richard M Ransohoff; Richard J Miller; Raymond Dingledine
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.